Objective: To determine efficacy and safety of rituximab treatment as a second-line immunotherapy treatment for autoimmune limbic encephalitis (ALE) and to determine factors associated with functional improvement and favorable outcome following rituximab treatment.
Autoimmune limbic encephalitis (ALE) is a recently recognized type of encephalitis mainly involving the limbic system. [1] [2] [3] [4] [5] [6] [7] Since NMDA receptor (NMDAR) encephalitis was first identified in 2007, 8 diagnosis of ALE has rapidly increased in concert with the discovery of novel autoantibodies. 2 Moreover, encephalitis of undetermined origin may have autoimmune etiology, 3, 4, 6, 7, 9 and recent diagnostic criteria allow for diagnosis of ALE even without the presence of a demonstrated autoantibody. 3, 4 Therefore, immunotherapy should be administered to patients when there is clinical suspicion of ALE and intensive surveys for infectious etiologies are unrevealing and antimicrobial therapies do not result in clinical improvement. 3, 4 Rituximab is a monoclonal antibody against CD20-positive B cells, which induces B-cell depletion. [10] [11] [12] [13] [14] Since the efficacy of rituximab in suppressing autoimmune disorders was established, 12, 15, 16 rituximab has been used to treat autoimmune neurologic disorders including multiple sclerosis, neuromyelitis optica, and myasthenia gravis. [10] [11] [12] 14, [17] [18] [19] One open-label study reported the efficacy of second-line immunotherapy including rituximab and cyclophosphamide for treatment of NMDAR encephalitis in patients who had insufficient response to first-line immunotherapies. 20 Rituximab does not affect innate immune system, immunoglobulin, or T-cell activity, and is relatively safe in terms of infectious adverse effects. 11, 14 Therefore, there may be broader indications for rituximab, including for patients with ALE with various autoantibodies or even without proven autoantibodies. To date, there is insufficient evidence addressing such clinical contexts.
In this study, we evaluated the efficacy and safety of rituximab (Class IV evidence) as a second-line immunotherapy for treatment of ALE and determined factors associated with favorable outcomes.
METHODS Standard protocol approvals, registrations, and patient consents. We collected data from a prospectively archived autoimmune encephalitis registry, the Korea Autoimmune-Synaptic and Paraneoplastic Encephalitis Registry (KASPER). KASPER was approved by the Institutional Review Board of Seoul National University Hospital. Enrolled patients or their next of kin gave written informed consent prior to enrollment in the registry.
Study population. Among patients in KASPER who underwent rituximab therapy between May 2012 and October 2014, the following patients were included for further analysis: (1) had a clinical diagnosis of ALE; (2) underwent 3 or more cycles of rituximab as a second-line immunotherapy; and (3) had a follow-up of at least 9 months. Clinical diagnosis of ALE included the following criteria: (1) limbic signs and symptoms (at least 2 of the following: memory disturbance, language dysfunction, seizures, psychiatric symptoms, affective disturbances, or abnormal movements) 21 ; (2) subacute onset or rapid progression of symptoms not explained by other neurologic disorders; (3) positive results of autoantibody tests or other evidence of CNS inflammation (including brain MRI revealing mediotemporal T2 hyperintensity without atrophy or CSF lymphocytic pleocytosis); and (4) exclusion of other possible etiologies of encephalitis. 3 Patients were screened for the presence of autoantibodies by immunostaining rat brain with patients' serum and CSF as previously described 22 and then tested for synaptic autoantibodies, including anti-NMDAR, leucine-rich-glioma-inactivated-1, contactin-associated-protein-like-2, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic-acid receptor-1, a-amino-3-hydroxy-5methyl-4-isoxazolepropionic-acid receptor-2, and g-aminobutyric acid receptor B using a cell-based immunocytochemistry method and classic paraneoplastic autoantibodies including anti-Hu, Yo, Ri, Ma2, CV2/CRMP5, and amphiphysin using an immunoblotting method (Euroimmun Ag, Lübeck, Germany). [23] [24] [25] [26] To exclude other etiologies of limbic encephalitis, patients underwent a battery of investigations for infectious etiologies including bacteria, virus, amoebas, and fungus using immunoassays, PCR analysis, and cultures from CSF or serum samples. 27 Patients without demonstrated autoantibodies were prescribed IV antiviral agents (acyclovir 30 mg/kg/d for 10-14 days) with or without broad-spectrum antibiotics as the initial empirical treatment. 27 If investigations for infectious etiologies were unrevealing and clinical and CSF profiles did not improve despite antimicrobial treatment, clinicians presumptively diagnosed ALE. Clinicians also screened for autoantibodies for systemic autoimmune diseases, and considered endocrine, renal, hepatic, or nutritional etiologies for encephalopathy, performing CSF cytology, wholebody PET, or tissue biopsies when clinically indicated.
We divided the final study population into 3 groups according to the autoantibody detection test results: (1) autoimmune synaptic encephalitis (synaptic autoantibody group); (2) classic paraneoplastic encephalitis (paraneoplastic autoantibody group); and (3) antibody-negative group.
Analysis of clinical, laboratory, and treatment profiles.
Based on medical records, we categorized symptoms into 8 groups: seizures, memory dysfunction, language dysfunction, psychiatric symptoms, cerebellar dysfunction, movement disorders, autonomic dysfunction, and consciousness decrement. Screening included chest and abdomen/pelvis CT as well as mammography and gynecologic evaluation.
Using MRI data from the time of diagnosis, we looked for mediotemporal T2 hyperintensities, abnormal T2 hyperintensities in any other area, and abnormal gadolinium enhancement. Using EEG data, also from the time of diagnosis, we investigated for the presence of regional/diffuse slowing and spiking in the temporal cortex. CSF analysis included CSF lymphocyte levels, checking for CSF lymphocytosis ($5 count/mm 3 ), and protein level elevation ($40 mg/dL). During rituximab administration, we assessed B-cell depletion via CD19 count.
First-line immunotherapy consisted of corticosteroids, IV immunoglobulins (IVIg), and plasmapheresis. 20 We defined 1 cycle of immunotherapy as 500-1,000 mg of methylprednisolone for 5 days, 0.4 g/kg of IVIg for 5 days, and 4 or more consecutive plasmapheresis treatments. Further, we analyzed the time lag from symptom onset to initiation of first-line immunotherapy, completion of first-line immunotherapy, whether the patient underwent combination therapy, and whether the patient received the same type of immunotherapy repetitively. We defined partial response to first-line immunotherapy as probable improvement of the most prominent symptom or possible improvement of the 2 most prominent symptoms, assessed after 2-4 weeks after the treatment, based on the subjective analysis of the investigators 20,28 ; further, we defined relapse as new onset or worsening of symptoms occurring after at least 2 months of stabilization. 20, 28 Before rituximab treatment, we screened all patients for hepatitis B and C. After presenting information about potential efficacy, safety, and cost issues of rituximab to patients and their caregivers, patients received rituximab (375 mg/m 2 weekly for 4 weeks) after an incomplete response to or relapse after first-line immunotherapy. All patients receiving rituximab were prescribed antihistamine and acetaminophen to prevent or ameliorate infusion-related adverse effects. We analyzed the time lag from symptom onset to rituximab administration, time lag from firstline treatment to rituximab treatment, number of rituximab treatment cycles, use of concomitant immunotherapy, and use of additional-monthly rituximab therapy (subsequent to the initial 4 weekly cycles). 29 Early rituximab therapy was defined as initiation of rituximab within 4 weeks of the last cycle of first-line treatment or detection of relapse. We also analyzed whether the profile of the first-line immunotherapy influenced the time lag from symptom onset to rituximab initiation.
Safety and outcomes analysis. We defined infusion-related adverse effects as any unfavorable or unintended hypersensitivity reaction that developed during the infusion of rituximab and infectious adverse effects as infectious complications related to rituximab therapy. Adverse events were recorded and classified according to the Common Terminology Criteria for Adverse Events (CTCAE) v 4.3. 28, 30 We also reported whether such adverse events resulted in early withdrawal of rituximab therapy. In addition, all patients had a complete blood count during every rituximab administration. We defined lymphopenia according to the CTCAE v 4.3. 30 We assessed functional status using the modified Rankin Scale (mRS) at initiation of the first-line immunotherapy, at initiation of rituximab, at the worst neurologic status, and at the last follow-up period. We defined favorable functional status at each time point as an mRS score of 0-2 and poor functional status at the worst neurologic status as an mRS score of 4-6. We also noted if the patient was admitted to the intensive care unit.
Finally, we designated outcome parameters as favorable mRS scores (0-2) and as mRS improvements (decrement of mRS score compared to score at initiation of rituximab treatment) at the last follow-up.
To evaluate the efficacy of rituximab treatment, we also reviewed patients from the KASPER registry who were diagnosed with ALE between May 2012 and October 2014 according to the above-mentioned diagnostic criteria, and who underwent first-line immunotherapies but not rituximab treatment as a control group. We compared clinical, treatment, and outcome profiles between the groups.
Statistical analysis. Results are presented as mean 6 standard deviation or number (%). We analyzed comparisons between groups using Student t test or analysis of variance, followed by Tukey b test for normally distributed variables. We compared categorical variables using the Pearson x 2 test and entered variables with p values ,0.10 into a binary logistic regression analysis. We used SPSS 21.0 (SPSS Inc., Chicago, IL) for all statistical analyses, and a 2-tailed p value ,0.05 to indicate significance.
RESULTS
Patient characteristics. Among the 93 patients initially included, we excluded 9 patients with years). There were 30 patients (37.5%) in the synaptic autoantibody group, 15 (18.8%) in the paraneoplastic autoantibody group, and 35 (43.8%) in the antibody-negative group. Results of the autoantibody detection test are shown in figure 1A . Twelve patients exhibited tumors; 5 patients had an ovarian teratoma (4 with NMDAR autoantibody and 1 antibody-negative), 2 had small-cell lung cancer (SCLC; 1 with anti-Hu autoantibody and 1 antibody-negative), and the remaining 5 patients had adrenal adenoma, breast cancer, neuroendocrine carcinoma, leukemia, or meningioma (associated with Ma2, NMDAR, anti-Hu autoantibodies, and 2 antibody-negative patients, respectively). The patients with ovarian teratoma, adrenal adenoma, breast cancer, or neuroendocrine carcinoma underwent complete surgical resection and patients with SCLC, breast cancer, or leukemia underwent chemotherapy. The patient with a meningioma was followed up without any treatment. Tumor status in all patients remained uniformly stable.
Patients underwent first-line immunotherapy for a median of 2 (IQR 1-2) cycles at 6.8 6 13.4 months from symptom onset. Forty-nine (61.3%) patients received 2 or more cycles, and 7 (8.8%) repetitively received the same first-line immunotherapy, which did not influence the initiation of rituximab therapy (9. The median mRS score was 3 (IQR 2-4) at initiation of first-line immunotherapies, 4 (IQR 3-5) at the worst neurologic status, and 4 (IQR 3-4) at initiation of rituximab. We detected a partial response to first-line immunotherapies in 25 (31.3%) patients. We observed rituximab administration with a mean lag of 12.1 6 8.7 months from the onset of symptoms. Forty-eight (60.0%) patients underwent early rituximab therapy and 43 (53.8%) had additional monthly rituximab therapy. Twelve (15.0%) patients received steroid therapy concomitantly with rituximab.
Every patient achieved a near-complete depletion of CD19-positive cells (#10/mm 3 ) during rituximab therapy. Thirty-seven (46.3%) patients had transient lymphopenia, but none of those cases was severe (lymphocyte count #200/mm 3 , grade $4) or sustained ($6 months). We noted infusion-related adverse effects in 5 (6.7%) patients, 4 with rash (grade 1) and 1 with dyspnea and palpitations (grade 2). None resulted in withdrawal of rituximab. There were reports of infection-related adverse effects in 9 (11.3%) patients, all with pneumonia (grade 3) at a median of 30 days (range 2-60) after rituximab initiation. There were no life-threatening (grade $4) or recurrent infectious adverse effects. Two adverse effects resulted in consequent withdrawal of rituximab after the third administration cycle.
We observed a median mRS score at the last follow-up of 2 (IQR 1-3). At last follow-up, 61 (76.3%) patients showed an mRS improvement and 55 (68.8%) displayed favorable mRS scores. Ten (12.5%) patients relapsed, with 8.4 6 3.1 months of delay.
Comparative analysis of groups with or without rituximab.
Compared to the control group, patients with rituximab treatment had a higher rate of cognitive and behavioral symptoms, more cycles of firstline immunotherapy, more frequent use of plasmapheresis, and decreased response to first-line immunotherapy. The rituximab group showed more mRS improvement (p 5 0.011), but did not achieve more favorable mRS scores at the last follow-up (p 5 0.442). Other clinical, laboratory, treatment, and outcome profiles were comparable between the 2 groups (table 1) . When all 161 patients were grouped according to the presence of at least partial response to first-line immunotherapy, favorable outcomes occurred more frequently in the responders to the first-line immunotherapy compared to the nonresponders (84.8% vs 47.6%; p , 0.001). However, among the 82 nonresponders, rituximab treatment resulted in more favorable outcomes compared to the patients without rituximab treatment (p 5 0.001, figure 2) . Comparative analysis of subgroups. The synaptic autoantibody group had a more favorable mRS score at first-line immunotherapy administration and longer follow-up duration compared to the antibodynegative group. The antibody-negative group had a better partial response to first-line immunotherapy compared to the paraneoplastic autoantibody group. We observed abnormal T2 hyperintensities more frequently in the antibody-negative group and cerebellar dysfunction more frequently in the paraneoplastic autoantibody group. Otherwise, we observed no differences in the profiles among the subgroups (table e- 1, figure 3 ).
Factors associated with favorable outcomes. Patients with mRS score improvement at the last follow-up were younger compared to those without such improvement (p 5 0.041). Otherwise, we observed no differences between groups in terms of outcomes (table e-1). Univariate analysis for mRS score improvement at the last follow-up, partial response to the first-line therapy, additional monthly rituximab cycles, and presence of psychiatric symptoms were associated with improved mRS scores. Other clinical factors, including detection or category of autoantibodies, profiles of first-line immunotherapy, or disease severity at each time course did not show any association (table e-2). Multivariate analysis showed that partial response to first-line therapy (p 5 0.037) and additional monthly rituximab cycles (p 5 0.010) were associated with mRS improvement (table 2) .
Univariate analysis for favorable mRS scores at the last follow-up, partial response to first-line therapies, and additional monthly rituximab cycles were associated with favorable mRS scores and admission to the intensive care unit was associated with unfavorable mRS scores. Multivariate analysis showed that partial response to first-line therapies (p 5 0.039) and additional monthly rituximab cycles (p 5 0.008) were associated with favorable mRS scores. Poor functional status at the worst neurologic status (p 5 0.037) was associated with unfavorable mRS scores at the last follow-up (tables e-2 and e-3). DISCUSSION This study revealed that rituximab is an effective second-line treatment for ALE, especially for patients who did not respond to first-line immunotherapy. Moreover, we observed efficacy of rituximab treatment regardless of autoantibody status. Further, additional monthly rituximab therapy and partial response to first-line immunotherapies were both associated with disease improvement and favorable outcome. On the other hand, poor mRS scores at the worst neurologic status was a predictor of a poor functional outcome. Additionally, rituximab showed a favorable safety profile, with infrequent severe adverse events. The most remarkable finding of the current study was that the effects of rituximab in the antibodynegative group and the paraneoplastic autoantibody group were comparable to those of the synaptic autoantibody group. Therefore, rituximab administration could be considered in clinically diagnosed ALE without demonstrated autoantibody after an insufficient response to first-line immunotherapies. Due to irreversible neuronal cell damage and frequent association with cancer, ALE associated with paraneoplastic autoantibodies is known to have a poor prognosis and be less responsive to immunotherapy. 4, 5 However, in this study, the relatively early induction of first-and second-line immunotherapies might have interrupted the progression of cell damage. Furthermore, the low rate of cancer in our study could be another explanation for the favorable outcomes.
The beneficial effect of additional monthly rituximab therapy was another remarkable finding of this study. In previous studies regarding the efficacy of rituximab in autoimmune neurologic disorders, rituximab was used with the standard regimen. 11, 12, 20, 28 However, numerous studies have reported on the beneficial effects of additional rituximab therapy for hemato-oncologic indications. For example, a repeated 4-week course of rituximab at 6-month intervals increased progression-free survival and complete response rates in indolent non-Hodgkin lymphoma, 31 and extended dosing with rituximab (8 consecutive weekly infusions) prolonged the duration of peripheral B-cell depletion. 14 Therefore, additional monthly rituximab might also be effective in inducing or maintaining ALE remission.
In the present study, partial response to first-line immunotherapies was associated with favorable outcomes, which could be considered an effect of rituximab rather than a delayed effect of first-line immunotherapy, considering the mean interval (5.3 6 16.1 months) between first-line immunotherapy and rituximab. This might be explained by some common mechanisms in ameliorating autoimmunity shared by the first-line immunomodulators and rituximab. 13 We also found that mRS scores of $4 at the worst neurologic status were associated with an unfavorable functional outcome, which was in agreement with previous reports. 20 The frequency of infectious or infusion-related adverse effects in the present study was comparable to those reported previously. 12, 14 The low incidence of severe infection during rituximab therapy could be attributed to steady immunoglobulin levels, T-cell activity, and an undisturbed innate immune system, which is crucial in fighting off infections during B-cell depletion. 11, 14 Therefore, rituximab has a substantial advantage in terms of safety, especially in cases of disturbed pathogen barriers, concomitant infections, or administration of multiple immunomodulators. 32 Given that rituximab showed substantial efficacy and safety, rituximab might be considered as a first-line immunotherapy for ALE, similar to antineutrophil-cytoplasmic antibody-associated vasculitis and neuromyelitis optica. 15, 16, 18, 19 We note, however, that rituximab did not further improve mRS scores, which might be partly due to administration of rituximab after lack of response to first-line immunotherapy in most cases (55/80, 68.8%). Prospective controlled studies are therefore warranted to establish efficacy of rituximab as a first-line immunotherapy. In addition, the lack of standardized treatment and follow-up protocols and absence of follow-up of serum immunoglobulin levels or autoantibody titers, which might have been a good indicator of response to rituximab, 33 are limitations in this study.
